← Product Code [MDA](/submissions/SU/subpart-e%E2%80%94surgical-devices/MDA) · K023136 # OLEEVA FABRIC (K023136) _Bio Med Sciences, Inc. · MDA · Oct 16, 2002 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/MDA/K023136 ## Device Facts - **Applicant:** Bio Med Sciences, Inc. - **Product Code:** [MDA](/submissions/SU/subpart-e%E2%80%94surgical-devices/MDA.md) - **Decision Date:** Oct 16, 2002 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 878.4025 - **Device Class:** Class 1 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use Oleeva Fabric is indicated for the management of hypertrophic scars and keloids. Consistent use of Oleeva Fabric can reduce hypertrophic scaring and keloid formation resulting from surgical or traumatic injury of the skin. Oleeva Fabric may be useful as a prophylaxis after surgical or traumatic dermal injury to aid in the prevention of hypertrophic scars and keloids. [As with the Predicate Device, we request OTC clearance for the modified device.] ## Device Story Oleeva Fabric is a topical silicone elastomer sheet used for scar management. Applied directly to skin, it functions as a physical barrier to reduce existing hypertrophic scars and keloids or prevent their formation following surgical or traumatic injury. Intended for over-the-counter (OTC) use by patients. Device provides a passive, non-invasive treatment modality for dermal injury recovery. ## Clinical Evidence Bench testing only. Biocompatibility testing conducted in conformity to EN/ISO 10993 guidelines, including Kligman Maximization, Primary Dermal Irritation, and Agarose Diffusion Cytotoxicity tests. ## Technological Characteristics Silicone elastomer sheeting. Biocompatibility verified via EN/ISO 10993 standards (Kligman Maximization, Primary Dermal Irritation, Agarose Diffusion Cytotoxicity). ## Regulatory Identification Silicone sheeting is intended for use in the management of closed hyperproliferative (hypertrophic and keloid) scars. ## Predicate Devices - Oleeva Fabric ([K982036](/device/K982036.md)) - Oleeva Foam ([K002109](/device/K002109.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ cienc 1111 Hamilton Street ♦ Allentown. PA 18101 Phone: (610) 432-8220 FAX: (610) 432-8240 Toll Free in U.S.: 1-800)-25-SILON (1-800-257-4566) http://www.silon.com # Attachment 4 K023136 ## 510 (k) Summary of Safety and Efficacy Oleeva® Fabric #### IDENTIFICATION Device Name: Oleeva Fabric Common or Usual Name: Elastomer, Silicone, for Scar Management #### CLASSIFICATION Class: Previous silicone scar management products had been unclassified. Classification Panel: Previous silicone scar management products have been subject to the General & Plastic Surgery classification panel - Medical Specialty Code SU. Product Code: MDA #### PRODUCT DESCRIPTION Oleeva Fabric is used topically to reduce hypertrophic scars and keloids. Consistent use of Oleeva may minimize scars resulting from traumatic or surgical injuries. Oleeva can reduce existing scars, and may be used after traumatic or surgical injury to aid in the prevention of new scars. #### INDICATIONS FOR USE Oleeva Fabric is indicated for the management of hypertrophic scars and keloids. Consistent use of Oleeva Fabric can reduce hypertrophic scaring and keloid formation resulting from surgical or traumatic injury of the skin. Oleeva Fabric may be useful as a prophylaxis after surgical or traumatic dermal injury to aid in the prevention of hypertrophic scars and keloids. #### SUBSTANTIAL EQUIVALENCE The new device is substantially equivalent to the existing Oleeva Fabric product (K982036), Oleeva Foam (K002109), as well as the other silicone sheeting products manufactured by Bio Med Sciences, Inc. #### BIOCOMPATIBILTY SUMMARY Oleeva Fabric passes the following test protocols which were conducted in conformity to EN/ISO 10993 guidelines. - . Kligman Maximization - Primary Dermal Irritation - Agarose Diffusion Cytotoxicity . {1}------------------------------------------------ Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is an abstract image of an eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 ### OCT 1 6 2002 Bio Med Sciences, Inc. Mark E. Dillon President 1111 Hamilton Street Allentown, Pennsylvania 18101 Re: K023136 Trade/Device Name: Oleeva® Fabric Regulation Name: Silicone sheeting for scar management Regulatory Class: Unclassified Product Code: MDA Dated: September 19, 2002 Received: September 20, 2002 Dear Mr. Dillon: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ Page 2 -- Mr. Mark E. Dillon This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Stupt Rlveda Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## Attachment 2 ### Indications for Use Statement | 510(k)
Number
(if known) | Oleeva Fabric, 510(k) K982036, | |--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device Name | Oleeva Fabric | | Indications
for Use | Oleeva Fabric is indicated for the management of hypertrophic scars and keloids. Consistent use of Oleeva Fabric can reduce hypertrophic scaring and keloid formation resulting from surgical or traumatic injury of the skin.

Oleeva Fabric may be useful as a prophylaxis after surgical or traumatic dermal injury to aid in the prevention of hypertrophic scars and keloids.

[As with the Predicate Device, we request OTC clearance for the modified device.] | PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE) | Prescription Use
(Per 21 CFR 801. 109) | OR | Over-The-Counter Use | |-------------------------------------------|----|----------------------| |-------------------------------------------|----|----------------------| Division Sign Off (Division Sign-Off) Division of General, Restorative and Neurological Devices 510(k) Number_________________________________________________________________________________________________________________________________________________________________ --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/MDA/K023136](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/MDA/K023136) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com